Navigation Links
Published Guidelines Further Support Use of Bioimpedance Measurement Technology for Early Assessment of Lymphedema
Date:6/12/2008

SAN DIEGO, June 12 /PRNewswire/ -- Recent guidelines published by the Clinical Resource Efficiency Support Team (CREST) provide further support for the use of bioimpedance technology for the early assessment of lymphedema.

The published guidelines for Northern Ireland titled "Guidelines for the Diagnosis, Assessment and Management of Lymphoedema" are the result of an expert panel including patients and healthcare professionals that reviewed the evidence for diagnosing, assessing and treating lymphedema.

The guidelines support the need for a shift in treatment focus from a reactive approach to one focused on the early assessment and early intervention of the condition. Bioimpedance technology featuring high sensitivity and specificity support this approach.

This surveillance method of diagnosis and treatment reflects recommendations recently published online in the journal Cancer, the official journal of the American Cancer Society.

To view the published guidelines online, please visit http://www.crestni.org.uk/crest_guidelines_on_the_diagnosis__assessment_and _ma nagement_of_lymphoedema.pdf. (Due to the length of the link, please copy and paste into your browser.)

About Lymphedema

Lymphedema is a condition that can cause significant swelling of the upper and lower extremities due to the build-up of excess lymph fluid. This can occur when the lymphatic system, which is responsible for draining excess fluid from the body and is a key component of the immune system, is damaged or altered. In breast cancer patients, this can occur after surgery, such as removal or biopsy of the lymph nodes, and/or radiation therapy. It is estimated that 6 percent to 40 percent of patients with breast cancer develop lymphedema, and that it often occurs within the first two years after surgery. For some cancer survivors and others at risk, a low level lymphedema can occur 10 years to 15 years following the initial primary treatment and develop into a condition that has a serious impact on overall health and quality of life. For more information about lymphedema, visit http://www.nci.nih.gov/cancerinfo/pdq/supportivecare/lymphedema/patient/.

About ImpediMed

ImpediMed is the world leader in the development and distribution of medical devices employing Bioimpedence Spectroscopy (BIS) technologies for use in non-invasive screening and monitoring of human disorders and diseases. ImpediMed's primary product range consists of a number of medical devices that enable surgeons, oncologists and radiation oncologists to detect early onset secondary lymphedema in breast cancer survivors, before the onset of symptoms that are detectable using the most commonly used clinical technique, and before the condition becomes a matter of lifelong management and impairs the quality of life of the cancer survivor. ImpediMed has the only medical BIS device with FDA clearance in the United States for the clinical assessment by health care providers of secondary lymphedema of the arm. For more information, visit http://www.impedimed.com.

Contacts: Wendy Lau or David Schull

Russo Partners LLC

(212) 845-4272

wendy.lau@russopartnersllc.com

david.schull@russopartnersllc.com


'/>"/>
SOURCE ImpediMed
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Biopure Phase III Orthopedic Trial Results Published in Journal of Trauma
2. Newly Published Study Shows OPKOs siRNA Bevasiranib Is Taken Up by Target Tissues in the Eye
3. Data Published at ASCO Find Correlation Between ChemoFx(R) Assay and Significantly Improved Overall Survival in Patients With Ovarian Cancer
4. Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings
5. Protein Tomography(TM) Reveals Molecular Mode of Action of Humax-EGFr Published in PNAS
6. Genmab A/S - Company Announcement: Novel Insights into HuMax-EGFr Mechanisms of Action Published in PNAS
7. Cardiac Safety Study of Stinger S-200 Published
8. Multi Merci Trial Results Published in Peer Reviewed Journal
9. Medifast Outperforms American Diabetes Association Diet by Twice the Weight Loss According to Published Study
10. IDM Pharma Announces Phase 3 Mifamurtide (L-MTP-PE) Study Demonstrating Improved Survival Published in the Journal of Clinical Oncology
11. Phase III Data Published for Once Monthly Dose of Risedronate to Treat Postmenopausal Osteoporosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... 2017 Solentim, the developer of instrumentation ... of a major new product line called the ... VIPS has been developed for automatically seeding single ... part of the process to generate clonally-derived cell ... more reliable solution when compared to traditional single ...
(Date:4/20/2017)... , April 20, 2017 ... "Global Biosimilar Pipeline and Market Prospects: Addressing Production ... report to their offering. ... "Global Biosimilar Pipeline and Market Prospects: ... Design" provides an in-depth assessment of the current trends ...
(Date:4/20/2017)... April 20, 2017  AbbVie (NYSE: ABBV), a ... (n=145/146) of chronic hepatitis C virus (HCV) infected ... 6 and compensated cirrhosis (Child-Pugh A) achieved sustained ... ) with its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir ... seen following 12 weeks of G/P treatment without ...
Breaking Medicine Technology:
(Date:4/28/2017)... ... April 28, 2017 , ... ... with the Home Care Association of America (HCAOA). This agreement allows HCAOA members ... services, as well as discounts on Accreditation University (AU) educational resources that help ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... ... to announce the integration of Microsoft(R) Word(TM) Online(TM), which enables sleep physicians to ... since it streamlines the reporting process and provides a familiar interface that does ...
(Date:4/28/2017)... ... 2017 , ... Horizon Blue Cross Blue Shield of New Jersey (BCBSNJ) announced ... its outlook as “stable.” At the same time, the ratings agency cautioned that the ... dip below “capital adequacy” thresholds required for its strong rating. , “Horizon is committed ...
(Date:4/28/2017)... ... April 28, 2017 , ... GlycoMark, Inc. announced today ... throughout the Northeast U.S. , GlycoMark is the only clinically available blood ... provides a clinically proven one- to two-week measure of hyperglycemic excursions, often related ...
(Date:4/28/2017)... ... April 28, 2017 , ... Ushio America ... lamps offer an instant energy-saving solution for F32T8 fluorescent lamps on most instant-start ... ballasts. These 50,000 hour rated lamps utilize the existing electronic ballast, saving labor ...
Breaking Medicine News(10 mins):